| Lead and Copper Rule | Health-Based | N/A | N/A | May 29, 2025 | Active | N/A |
| Lead and Copper Rule | Health-Based | N/A | N/A | May 29, 2025 | Active | N/A |
| Lead and Copper Rule | Health-Based | N/A | N/A | May 29, 2025 | Active | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 12, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 10, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 10, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 10, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 10, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 21, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 21, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 9, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 9, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 9, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 9, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 11, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 29, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 29, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 29, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 29, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 18, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 18, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 18, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 18, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 8, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 8, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 8, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 8, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Nov 8, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Nov 8, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Nov 8, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Nov 8, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Nov 8, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Nov 8, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Nov 8, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Nov 8, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 7, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 7, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 7, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 7, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0135 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0135 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0135 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0135 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| E. COLI | Monitoring | 0 | N/A | Jul 21, 2023 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Jul 21, 2023 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Jul 21, 2023 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Jul 21, 2023 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0184 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0184 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0184 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0184 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 8, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 8, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 8, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 8, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 8, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0157 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0157 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0157 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0157 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 5, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0135 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0135 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0135 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0135 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0109 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0109 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0109 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0109 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 8, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 17, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 17, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 17, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 17, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 7, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 7, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 7, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 7, 2022 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Combined Uranium | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Combined Uranium | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Combined Uranium | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Combined Uranium | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 11, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 11, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 11, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 11, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| E. COLI | Monitoring | 0 | N/A | Jun 12, 2021 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Jun 12, 2021 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Jun 12, 2021 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Jun 12, 2021 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2021 | Resolved | N/A |
| E. COLI | Monitoring | 0 | N/A | Feb 24, 2021 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Feb 24, 2021 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Feb 24, 2021 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Feb 24, 2021 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |